stockrow
Friday 6 November 2026
Export BHVN’s income statement to Excel — free account
Biohaven Ltd.
BHVN Healthcare Biotechnology
- EPS
- +47.8%
- Free cash flow
- +26.6%
- Total debt
- −1.48%
Quarter to September 2026, against a year earlier
14.28
0.38
+2.73%
Follow BHVN
Alert me
Biohaven Ltd. (BHVN) Net income
Biohaven Ltd.'s net income for fiscal 2025 was −$738.8M, compared with −$846.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$542.7M. Over the past ten years it has ranged from −$846.4M (fiscal 2024) to −$10.1M (fiscal 2015); the current reading is higher than 18% of that period. Biohaven Ltd. ranks 589th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$738.8M | — |
| FY2024 | −$846.4M | — |
| FY2023 | −$408.2M | — |
| FY2022 | −$570.3M | — |
| FY2021 | −$213.8M | — |
| FY2020 | −$118.7M | — |
| FY2019 | −$528.8M | — |
| FY2018 | −$240.9M | — |
| FY2017 | −$127.2M | — |
| FY2016 | −$63.5M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$129.3M | — |
| Jun 2026 | −$137.3M | — |
| Mar 2026 | −$130.5M | — |
| Dec 2025 | −$145.6M | — |
| 40 more quarters | Free account |
Against its own ten years
Low −$846.4M
High −$10.1M
Ten-year median
−$240.9M
Current reading's percentile
18
Net income against peers
| Company | Net income |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $314.3M |
| ADMA ADMA Biologics Inc compare | $182.4M |
| VCEL Vericel Corporation compare | $33.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$61.7M |
| IMNM Immunome, Inc. compare | −$254.3M |
| CLDX Celldex Therapeutics, Inc. compare | −$300.5M |
| VERA Vera Therapeutics, Inc. compare | −$401.9M |
| BHVN Biohaven Ltd. | −$542.7M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$652.4M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item